Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Feb 12, 2024

(R) Cantargia reports new data reinforcing nadunolimab as cancer combination therapy

Feb 7, 2024

Invitation to presentation of Cantargia’s year-end report 2023 on February 22 at 3.00 p.m. CET

Jan 9, 2024

(R) Cantargia reports phase I clinical progress in the CAN10 project

Nov 30, 2023

(R) New number of shares and votes in Cantargia

Nov 24, 2023

Cantargia reports new preclinical data confirming the potential of nadunolimab and CAN10

Nov 20, 2023

(R) Third party withdraws appeal related to Cantargia patent

Nov 10, 2023

(R) Cantargia publishes interim report for third quarter 2023

Nov 3, 2023

(R) Nomination Committee appointed ahead of 2024 Annual General Meeting

Oct 30, 2023

(R) Cantargia has completed a directed share issue of approximately SEK 59 million

Oct 26, 2023

Invitation to presentation of Cantargia’s report for the third quarter of 2023 on November 10 at 3.00 p.m. CET

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye